<DOC>
	<DOCNO>NCT01217034</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy combination therapy Transcatheter Arterial Chemoembolization ( TACE ) sorafenib compare TACE alone patient unresectable hepatocellular carcinoma ( HCC ) candidate surgical resection percutaneous ablation therapy .</brief_summary>
	<brief_title>Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib</brief_title>
	<detailed_description>TACE sorafenib Group Sorafenib administrate dose 400mg o.d . first TACE . After 2days drug rest , TACE conduct . Sorafenib resume dose 400mg o.d . 3 day TACE ( resumption day postpone 21 day TACE ) . When tolerability confirm 1 week resumption , dose sorafenib increase 400mg b.i.d . When tumor increase , TACE repeat . Control group TACE conduct schedule day . When tumor increase , TACE repeat . The treatment regimen continue untreatable progression define follow : - Child-Pugh grade C - Tumor growth ( 125 percent baseline status ) - Vascular invasion ( Vp3 , Vp4 ) - Extra hepatic spread size 10mm</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients age 20 Years 2 . Patients fully inform study beforehand sign informed consent participate study . 3 . Patients expect live 12 week . 4 . Patients diagnose typical HCC biopsy , cytology , diagnostic image dynamic CT ( MRI ) .Typical HCC define AASLD criterion . 5 . Patients complete resection tumor hepatectomy complete tumor necrosis local tumor necrosis therapy ( RFA ) expect succeed . 6 . Patients tumor confirm liver treat TACE ( maximum diameter equal less 10cm , maximum number nodule equal less 10 ) . 7 . Patients viable measurable target lesion . 8. patient one history TACE therapy . 9. patient ECOG PS ( Performance Status ) Score 0 1 . 10. patient ChildPugh class A . 11 . Patients laboratory value meet follow criterion : 1 . Hemoglobin ≥ 8.5 g/dl 2 . Granulocytes ≥ 1500/mm3 3 . Platelet count ≥ 50,000 /mm3 4 . Total serum bilirubin ≤ 3 mg/dl 5 . AST ALT ≤ 6 time upper limit normal 6 . Serum creatinine ≤ 1.5 time upper limit normal 1 . History malignant tumor , exclude follow case : 1 . Curatively treat early stage cancer low risk recurrence , carcinoma situ cervix , basal cell carcinoma , superficial bladder tumor , early gastric cancer . 2 . Malignant tumor curatively treat 3 year prior study entry recur since 2 . Cardiac disease meet follow criterion : 1 . NYHA Class III higher congestive heart failure 2 . History symptomatic coronary artery disease myocardial infarction within 6 month enrollment 3 . Arrhythmia require control antiarrhythmic drug betablockers digoxin 3 . Serious active infection , except HBV HCV 4 . History HIV infection 5 . Renal dialysis 6 . Diffuse tumor lesion 7 . Extrahepatic metastasis 8 . Vascular invasion 9 . Intracranial tumor 10 . Preexisting history hepatic encephalopathy 11 . Clinically uncontrolled ascites pleural effusion 12 . Clinically severe gastrointestinal bleeding within 4 week start treatment 13 . Esophageal and/or gastric varix high risk bleed 14 . History thrombosis and/or embolism within 6 month start treatment 15 . History receive follow therapy : 1 . Systemic chemotherapy advance HCC ( include sorafenib therapy ) 2 . Local therapy , radiofrequency ablation , TACE , hepatic arterial infusion within 3 month start treatment 3 . Current treatment CYP3A4 induce agent 4 . Invasive surgery within 4 week start treatment 5 . History allogenic transplantation 6 . History bone marrow transplant haemopoietic stem cell transplant within 4 week start study 16 . Unable take oral medication 17 . Gastrointestinal problem may affect absorption pharmacokinetics study drug 18 . Use drug may affect absorption pharmacokinetics study drug 19 . Concurrent disease disability may affect evaluation effect study drug 20 . Enrollment another study within 4 week study entry 21 . Female patient pregnant , lactate , possibly pregnant , plan become pregnant 22 . Risk allergic reaction study drug 23 . Drug abuse physical , psychological , social problem may interfere participation study evaluation study result 24 . Any condition could jeopardize safety patient compliance study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Transcatheter arterial chemoembolization</keyword>
	<keyword>TACE</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Time untreatable progression</keyword>
	<keyword>TTUP</keyword>
</DOC>